GeneCentric Therapeutics Inc selects Exemplar ELN Professional
Sapio Sciences LLC is pleased to announce that GeneCentric Therapeutics Inc has selected Exemplar ELN Professional as its LIMS/ELN Platform.
Exemplar ELN Professional is the most feature rich release in Sapios history, including features to enable high levels of data representations, analysis and visualizations.
Exemplar ELN Pro combines the best of traditional ELN capabilities to support scientists with their ad hoc experimentation, while now also leveraging Sapios 10+ years of experience in tracking complex workflows to also enable traditional LIMS features, including
- Drag and Drop Creation of Workflow Templates
- Easy Creation and Tracking of Complex Templatized Processes
- MS Office and R Statistics Integration
- Request Management & Integrated Sample Registration System
- Consumable, Instrument and Storage Management
- Complete NGS Pipeline out of the box
- Graphical Dashboards for Tracking Lab Operational Metrics like Turnaround Times
- Availability as a SAAS Hosted or as an On-Premise Solution
According to Kevin Cramer, CEO of Sapio, Pharma and Biotech companies are challenged to find best in class LIMS and ELN solutions to support their lab operations and researchers. Typically, this meant buying two distinct solutions and undertaking a costly and cumbersome integration process. With Exemplar ELN Professional, an organization gets best in class LIMS and ELN functionality in a single solution leading to significant savings in time and money versus buying point solutions.
Our selection of Sapios Exemplar ELN Pro resulted following an extensive assessment of the leading LIMS systems, said Dr. Myla Lai-Goldman, CEO of GeneCentric Therapeutics, Inc.; With Exemplar ELN, we anticipate a comprehensive and easily maintained lab operations system to support our ongoing research as well as industry and institution collaborations to advance novel cancer therapies.
About GeneCentric Therapeutics, Inc.
GeneCentric Therapeutics, Inc., based in Research Triangle Park, N.C., is applying proprietary technology to identify drug responder populations that enable the development of precision cancer drugs while improving patient outcomes. Our initial approach applies our Cancer Subtype Platform (CSP®) to parse the complexity of tumor biology and generate genomic signatures. This approach yields high-resolution cancer subtypes with the potential to function as universal biomarkers for susceptibility to immune-based, targeted and other therapies. In commercializing our technology through strategic collaborations with pharmaceutical and biotech companies, we are defining responder populations based on subtypes throughout the drug development cycle. For more information, please visit www.GeneCentric.com.